A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses

IntroductionMetastatic uveal melanoma (MUM) has a poor prognosis and treatment options are limited. These patients do not typically experience durable responses to immune checkpoint inhibitors (ICIs). Oncolytic viruses (OV) represent a novel approach to immunotherapy for patients with MUM.MethodsWe...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Katherine E. R. Smith, Kah-Whye Peng, Jose S. Pulido, Adam J. Weisbrod, Carrie A. Strand, Jacob B. Allred, Alysha N. Newsom, Lianwen Zhang, Nandakumar Packiriswamy, Timothy Kottke, Jason M. Tonne, Madelyn Moore, Heather N. Montane, Lisa A. Kottschade, Robert R. McWilliams, Arkadiusz Z. Dudek, Yiyi Yan, Anastasios Dimou, Svetomir N. Markovic, Mark J. Federspiel, Richard G. Vile, Roxana S. Dronca, Matthew S. Block
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-10-01
Colecção:	Frontiers in Immunology
Assuntos:	oncolytic virus uveal melanoma phase 1 immunotherapy epitope spreading
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1279387/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!